This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Drug-induced obesity

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • the potential for iatrogenic weight gain is more common than is generally appreciated
  • Drug-induced obesity may result from therapeutic use of:
    • corticosteroids
      • have potent weight-promoting actions, particularly at higher doses
      • the characteristic alteration of body composition is accompanied by insulin resistance
    • psychotropic drugs
      • many psychotropic drugs are associated with weight gain - has more recently been highlighted as a concern with atypical antipsychotics such as olanzapine and clozapine
      • risks of excessive weight gain and the development of the metabolic syndrome call for careful monitoring
    • anti-retroviral agents
      • nucleoside reverse transcriptase inhibitors, e.g stavudine and zidovudine promote central adiposity, as well as subcutaneous lipoatrophy
    • thiazolidinediones
      • agonists for peroxisome proliferator-activated receptor-gamma e.g. pioglitazone
        • reduce insulin resistance and can improve a range of cardiovascular risk factors in people with type 2 diabetes
        • weight gain averaging 3-4 kg is common during the first few months of thiazolidinedione therapy, tending to stabilise thereafter (1)

Reference:

  1. British Heart Foundation (November 2004). Factfile - the causes of obesity.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.